Working… Menu
Trial record 58 of 333 for:    DABIGATRAN

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01241539
Recruitment Status : Completed
First Posted : November 16, 2010
Results First Posted : July 27, 2012
Last Update Posted : April 7, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The current study will allow the assessment of pharmacokinetics, pharmacodynamics, elimination rate and clearance of dabigatran etexilate during and following haemodialysis in ESRD patients.

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Kidney Failure, Chronic Drug: Dabigatran etexilate Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Open Label, Non Randomized, Multiple Dose Phase I Study to Investigate the Elimination, Pharmacokinetics, Pharmacodynamics and Safety of Dabigatran Etexilate (Pradaxa) Under Steady State Conditions Before, During and After Haemodialysis in Patients With End Stage Renal Disease (ESRD) Undergoing Regular Haemodialysis
Study Start Date : November 2010
Actual Primary Completion Date : May 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Dabigatran etexilate 110 mg
Capsule, oral
Drug: Dabigatran etexilate
110 mg capsule

Experimental: Dabigatran etexilate 75 mg
Capsule, oral
Drug: Dabigatran etexilate
75 mg capsule

Experimental: Dabigatran etexilate 150 mg
Capsule, oral
Drug: Dabigatran etexilate
150 mg capsule

Primary Outcome Measures :
  1. Dialysis Clearance of Dabigatran [ Time Frame: 4 hours ]
    Dialysis clearance of dabigatran from blood (CLD,b) and dialysis clearance of dabigatran from plasma (CLD) were calculated and indicate how quickly dabigatran is cleared out from blood or plasma.

  2. Extent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis [ Time Frame: 4 hours ]
    Extent of dabigatran that is removed from blood during one complete 4-hour cycle of dialysis was computed by the difference of plasma concentration at the start and at the end of dialysis relative to the start concentration and is therefore measured as a percentage.

  3. Plasma Concentration Extraction Ratio [ Time Frame: 4 hours ]
    Plasma concentration extraction ratio was measured directly at the dialysis machine and computed as the difference of the predialysis plasma concentration and the postdialysis plasma concentration relative to the predialysis concentration on the percentage scale (minimum: 0 percent of extraction (worst), maximum: 100 percent of extraction).

Secondary Outcome Measures :
  1. Area Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h) [ Time Frame: Days 2 and 3 ]
    Area under the concentration-time curve of total and free dabigatran in plasma over the time interval from 0 to 8 hours after the second and third administration of dabigatran.

  2. Maximum Plasma Concentrations of Dabigatran (Cmax) [ Time Frame: Days 2 and 3 ]
    Maximum measured concentration of total and free dabigatran in plasma after the second and third administration of dabigatran.

  3. Time to Maximum Plasma Concentration (Tmax) [ Time Frame: Day 3 ]
    Time to maximum plasma concentration of total and free dabigatran in plasma after the third administration of dabigatran.

  4. Coagulation Parameters [ Time Frame: Day 3 ]
    Assessment of blood coagulation parameters 'activated partial thromboplastin time' (aPTT) and 'factor IIa inhibition' (anti-FIIa) measured with the diluted thrombin time assay. Time to the formation of a fibrin clot (coagulation) is measured in seconds.

  5. Safety and Tolerability [ Time Frame: 2 periods of 5 days each ]
    Tolerability refers to the number of non-tolerable patients as assessed through the subjective examination of adverse events (AE). Safety refers to the number of patients with treatment emergent AEs. These numbers are presented on the overall Dabigatran treatment.

  6. Additional Safety Parameters [ Time Frame: 2 periods of 5 days each ]
    By study design abnormalities could be due to dialysis or Dabigatran.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • End stage renally disease (ESRD), undergoing haemodialysis
  • ESRD patients in relatively good health
  • Age 21 - 60 years inclusive
  • Signed and dated written informed consent prior to admission to the study

Exclusion criteria:

  • Clinically relevant laboratory or physical examination abnormalities (except for renal function tests or deviation of clinical laboratory values) that are related to renal impairment
  • Moderate and severe concurrent liver function impairment
  • Surgery of gastrointestinal tract (except appendectomy or herniotomy) or evidence of significant gastrointestinal motility problems
  • Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding
  • Intake of medication, which influences the blood clotting
  • Subjects not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
  • For women with childbearing potential: no reliable contraception
  • Participation in another trial with an investigational drug (<2 months prior to administration or during trial)
  • Scheduled to receive a donor kidney transplant during the course of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01241539

Layout table for location information
1160.121.1 Boehringer Ingelheim Investigational Site
Berlin, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT01241539     History of Changes
Other Study ID Numbers: 1160.121
2010-021819-16 ( EudraCT Number: EudraCT )
First Posted: November 16, 2010    Key Record Dates
Results First Posted: July 27, 2012
Last Update Posted: April 7, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Failure, Chronic
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action